The Yellowstone Crohn’s Disease Clinical Research Program
The YELLOWSTONE Program is a series of Phase 3 clinical studies for people with moderately to severely active Crohn’s disease. These studies will evaluate the safety and effectiveness of an oral investigational study drug (ozanimod) which is taken once daily. Ozanimod is not a biologic, injection or infusion. Ozanimod is an immune regulator designed to change the body’s immune system response (when the body defends itself), potentially reducing inflammation and overall disease activity. The goal is to potentially help people living with this disease reduce symptoms (remission/response).